117 related articles for article (PubMed ID: 28364163)
1. Envisaging an alpha therapy programme in the atomic energy establishments: the priorities and the nuances.
Basu S; Banerjee S
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1244-1246. PubMed ID: 28364163
[No Abstract] [Full Text] [Related]
2. Developing a dedicated comprehensive α-radionuclide therapy program: should this be the vision of the atomic energy programs in the next decade?
Basu S; Banerjee S
Nucl Med Commun; 2017 Feb; 38(2):103-105. PubMed ID: 27906780
[No Abstract] [Full Text] [Related]
3. Potential and pitfalls of therapy with alpha-particles.
Welch MJ
J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
[No Abstract] [Full Text] [Related]
4. Future prospects for targeted alpha therapy.
Allen BJ
Curr Radiopharm; 2011 Oct; 4(4):336-42. PubMed ID: 22202156
[TBL] [Abstract][Full Text] [Related]
5. Alpha particle therapy poised to become new line of cancer treatment.
Kotz D
J Nucl Med; 1998 Feb; 39(2):17N-19N, 36N. PubMed ID: 9476918
[No Abstract] [Full Text] [Related]
6. Cyclotron production of Ac-225 for targeted alpha therapy.
Apostolidis C; Molinet R; McGinley J; Abbas K; Möllenbeck J; Morgenstern A
Appl Radiat Isot; 2005 Mar; 62(3):383-7. PubMed ID: 15607913
[TBL] [Abstract][Full Text] [Related]
7. The Future of Radioligand Therapy: α, β, or Both?
Haberkorn U; Giesel F; Morgenstern A; Kratochwil C
J Nucl Med; 2017 Jul; 58(7):1017-1018. PubMed ID: 28408527
[No Abstract] [Full Text] [Related]
8. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
Zalutsky MR
J Nucl Med; 2006 Aug; 47(8):1238-40. PubMed ID: 16882999
[No Abstract] [Full Text] [Related]
9. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
Allen BJ
Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184
[No Abstract] [Full Text] [Related]
10. Letter from the Editors.
Sathekge MM; Bouchelouche K
Semin Nucl Med; 2020 Mar; 50(2):115-117. PubMed ID: 32172794
[No Abstract] [Full Text] [Related]
11. Nuclear energy and medicine: the Canadian connection.
Gray C
Can Med Assoc J; 1984 Feb; 130(3):299-304. PubMed ID: 6692215
[No Abstract] [Full Text] [Related]
12. The magic-bullet: moving the concept towards reality – part II.
Elgqvist J
Curr Radiopharm; 2011 Oct; 4(4):281-2. PubMed ID: 22202150
[No Abstract] [Full Text] [Related]
13. [Alpha-radioimmunotherapy: a review of recent developments].
Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
[TBL] [Abstract][Full Text] [Related]
14. [Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].
Ménager J; Gorin JB; Fichou N; Gouard S; Morgenstern A; Bruchertseifer F; Davodeau F; Kraeber-Bodéré F; Chérel M; Gaschet J; Guilloux Y
Med Sci (Paris); 2016 Apr; 32(4):362-9. PubMed ID: 27137693
[TBL] [Abstract][Full Text] [Related]
15. Radiolanthanides in nuclear medicine.
Rösch F; Forssell-Aronsson E
Met Ions Biol Syst; 2004; 42():77-108. PubMed ID: 15206100
[No Abstract] [Full Text] [Related]
16. The International Atomic Energy Agency's work in the field of nuclear medicine.
COHEN M; DUDLEY RA; GOMEZ-CRESPO G; PEARSON JD; TSIEN KC; VETTER H
Nurs Outlook; 1962 Jul; 2():435-46. PubMed ID: 13880283
[No Abstract] [Full Text] [Related]
17. Some notes on atomic medicine.
BEHRENS C
J S C Med Assoc; 1955 May; 51(5):155-9. PubMed ID: 14382062
[No Abstract] [Full Text] [Related]
18. [Notes on atomic medicine].
BEHRENS CF
Dtsch Med Wochenschr; 1950 Oct; 75(43):1423-5. PubMed ID: 14793142
[No Abstract] [Full Text] [Related]
19. Calculation of potential alpha energy concentrations.
Sheets RW; Thompson CC
Health Phys; 1993 May; 64(5):552. PubMed ID: 8387984
[No Abstract] [Full Text] [Related]
20. The first decade of atomic medicine.
WARREN S
J Fla Med Assoc; 1956 Sep; 43(3):252-4. PubMed ID: 13357706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
